PT  - JOURNAL ARTICLE
AU  - Takehiro Otoshi
AU  - Ryoji Kato
AU  - Ryoko Shimizu
AU  - Daichi Hujimoto
AU  - Takahisa Kawamura
AU  - Koji Tamai
AU  - Takeshi Matsumoto
AU  - Kazuma Nagata
AU  - Kyoko Otsuka
AU  - Atsushi Nakagawa
AU  - Kojiro Otsuka
AU  - Keisuke Tomii
TI  - Clinical features and outcomes of patients with diffuse alveolar hemorrhage during antithrombotic therapy
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P3776
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P3776.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P3776.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Introduction: Antithrombotic therapy has been increasingly recognized as a cause of diffuse alveolar hemorrhage(DAH). However, there have been few reports on clinical features and outcomes of patients with DAH during antithrombotic therapy.Aims: To clarify features and mortality of DAH during antithrombotic therapy.Methods: We retrospectively reviewed 54 patients who were diagnosed with DAH from January 2009 to July 2013. DAH was confirmed when bronchoalveolar lavage aliquots were progressively more hemorrhagic.Results: Twenty-eight patients were associated with antithrombotic thrapy, but 7 of them had another cause of DAH (1 patient had drug-induced pneumonia, 2 patients had acute exacerbation of interstitial pneumonia, 3 patients had anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis, and 1 patient had thrombocytopenia due to myelodysplastic syndromes). Among the remaining 21 patients, 15 (71%) had heart failure and 11 (52%) had renal failure. Five (24%) of the 21 patients died, and 3 (14%) of them needed dialysis. The number of patients who needed dialysis during treatment of DAH was statistically higher among non-survivors than among survivors (60% vs. 13%, P=0.03)Conclusions: DAH due to antithrombotic therapy occurred frequently among patients with heart failure or renal failure. Patients who needed dialysis during treatment of DAH had poorer outcomes.